Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhencao Tongfengxiao is a traditional Chinese medicine (TCM) formulation developed by Guangzhou Lanyun Pharmaceutical Research Co., Ltd. for the management of hyperuricemia and gout. The product is typically composed of a blend of herbal extracts, including species such as *Smilax glabra* (Tu Fu Ling) and *Plantago asiatica* (Che Qian Cao), which are traditionally used to clear heat and promote diuresis. The therapeutic mechanism involves the inhibition of xanthine oxidase, the enzyme responsible for uric acid synthesis, and the modulation of renal urate transporters such as URAT1 to enhance the excretion of uric acid. By lowering serum uric acid levels and providing anti-inflammatory support, Zhencao Tongfengxiao aims to alleviate gout symptoms and prevent the recurrence of gouty arthritis flares.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhencao Tongfengxiao.